MedTrace Logo

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

NCT01691209 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-08-13

No results posted yet for this study

Summary

The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).

Conditions

  • Dermatitis, Atopic

Interventions

DEVICE

Phoenix (BAY81-2996)

Topical formulation applied to the skin

DRUG

1% Hydrocortison cream

1% Hydrocortison cream applied to the skin

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-04-30
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691209 on ClinicalTrials.gov